Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified product portfolio and effective execution across its various business units.</li><li>The company achieved an impressive 15% operationally and 13% organically in sales growth, surpassing the high-end guidance range of 7% to 9%.</li><li>Additionally, all business units and regions recorded notable double-digit growth during the quarter, reflecting strong market penetration and execution.</li></ul>

Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified product portfolio and effective execution across its various business units.The company achieved an impressive 15% operationally and 13% organically in sales growth, surpassing the high-end guidance range of 7% to 9%.Additionally, all business units and regions recorded notable double-digit growth during the quarter, reflecting strong market penetration and execution.

Boston Scientific Corporation: What Are Their Latest Investments in Innovative Technologies? - Major Drivers

<ul><li>Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by surpassing set financial goals.</li><li>Throughout the year, total company operational sales grew by 15% and organic sales by 14%, exceeding the high-end guidance range of 8% to 10%.</li><li>Operational sales growth for the full year was registered at 13%, and organic sales grew by 12%.</li></ul>

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by surpassing set financial goals.Throughout the year, total company operational sales grew by 15% and organic sales by 14%, exceeding the high-end guidance range of 8% to 10%.Operational sales growth for the full year was registered at 13%, and organic sales grew by 12%.

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

<ul><li>Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams.</li><li>In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 '22.</li><li>The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 '22, exceeding the guidance range of $0.46 to $0.48.</li></ul>

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product innovations, clinical evidence, and the dedication of global teams.In Q3, the company achieved remarkable operational and organic growth, with total sales increasing by 11% operationally and 10% organically compared to Q3 '22.The adjusted EPS for Q3 reached $0.50, a 15% increase over Q3 '22, exceeding the guidance range of $0.46 to $0.48.

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

<ul><li>Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter.</li><li>In the second quarter, Boston Scientific witnessed a 12% growth in total company sales.</li><li>In the peripheral intervention segment, sales surged by 13% organically, while cardiology delivered impressive organic sales growth of 13%.</li></ul>

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter.In the second quarter, Boston Scientific witnessed a 12% growth in total company sales.In the peripheral intervention segment, sales surged by 13% organically, while cardiology delivered impressive organic sales growth of 13%.

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Boston Scientific Corporation: What Are Their Latest Investments in Innovative Technologies? - Major Drivers

Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified...

Baptista Research

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by...

Baptista Research

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product...

Baptista Research

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter. In the second quarter, Boston Scientific...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Boston Scientific Corporation: What Are Their Latest Investments in Innovative Technologies? - Major Drivers

Boston Scientific Corporation reported robust first-quarter 2024 results that exceeded expectations, driven by an expansive and diversified...

Baptista Research

Boston Scientific Corporation: Axonics & Other Acquisitions Are Potential Game Changers? - Major Drivers

Boston Scientific Corporation experienced an exceptional performance in 2023, delivering one of the strongest years in the company's history by...

Baptista Research

Boston Scientific Corporation: Soaring High With New Products & The Acquisition Of Axonics! - Major Drivers

Boston Scientific Corporation delivered an all-around beat in the previous quarter, demonstrating sustained momentum driven by new product...

Baptista Research

Boston Scientific Corporation: Delving Into Double-Digit Growth - Must-Know Info for Every Investor! - Major Drivers

Boston Scientific Corporation delivered a solid result and managed an all-around beat last quarter. In the second quarter, Boston Scientific...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...